Applied down by a third on latest galactosaemia stumble

7 October 2022

US biopharma Applied Therapeutics (Nasdaq: APLT) has suffered another setback in its development of AT-007 in galactosemia.

There are currently no approved treatments for the disease, which is a rare, hereditary disorder of carbohydrate metabolism that affects the body's ability to convert galactose to glucose.

After 12 months of treatment, the use of AT-007 has failed to show statistical significance in the ACTION-Galactosemia Kids Phase III trial, thereby failing to meet the study’s primary endpoint.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK